ArticlePediatric research2026
Pulmonary hypertension, inhaled nitric oxide, and retinopathy of prematurity: evidence from the U.S. national database.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study aimed to examine the association of pulmonary hypertension (PH) and the use of inhaled nitric oxide (iNO) with retinopathy of prematurity (ROP) in very low birth weight (VLBW) infants.
methodsUtilizing the United States National Inpatient Sample (NIS) database, VLBW infants were identified. Chi-square and Fisher's exact tests were used to calculate unadjusted odds ratios (ORs) for the presence of ROP in relation to PH and iNO therapy. Adjusted odds ratios (aORs) were calculated using logistic regression while controlling for potential confounders.
resultsAmong 1,007,141 infants, 30,401 (3%) had PH. ROP was diagnosed more frequently with PH (22.3% vs 13.6%; aOR: 1.32, 95% CI: 1.28-1.36, p < 0.001). Severe ROP was less frequent in iNO-treated PH infants (4.33% vs 5.35%; aOR: 0.82, 95% CI: 0.70-0.96, p = 0.02). In extremely low birth weight (ELBW) infants with PH, iNO use was associated with lower rates of severe ROP (aOR: 0.68, 95% CI: 0.57-0.81, p < 0.001).
conclusionsPH is associated with an increased risk of ROP. iNO therapy is associated with a decreased prevalence of severe ROP in PH-affected infants. Further studies are needed to assess the early use of vascular modulators in mitigating the risk for ROP. IMPACT: Premature infants diagnosed with pulmonary hypertension are at increased risk for ROP. Severe ROP is less encountered when inhaled nitric oxide was used in this vulnerable population. This is the first study to assess the interaction between pulmonary hypertension, its treatment, and the development of ROP in premature infants. The study suggests the need for future studies to assess the efficacy of early use of vascular modulators in mitigating the risk of ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.